Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
Fujimasa TadaAtsushi HiraokaToshifumi TadaMasashi HirookaKazuya KariyamaJoji TaniMasanori AtsukawaKoichi TakaguchiEi ItobayashiShinya FukunishiKunihiko TsujiToru IshikawaKazuto TajiriHironori OchiHidenori ToyodaChikara OgawaTakashi NishimuraTakeshi HatanakaSatoru KakizakiNoritomo ShimadaKazuhito KawataAtsushi NaganumaHisashi KosakaTomomitsu MatonoHidekatsu KurodaYutaka YataHideko OhamaKazuhiro NousoAsahiro MorishitaAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiKeisuke YokohamaHiroki NishikawaMichitaka ImaiYohei KoizumiShinichiro NakamuraHiroko IijimaMasaki KaiboriYoichi HiasaTakashi Kumadanull nullPublished in: Journal of gastroenterology (2023)
Atez/Bev might be an effective therapeutic option in patients with EGV, when appropriate endoscopic treatment for EGV is performed.